Population pharmacokinetics of siltuximab: impact of disease state
Author:
Funder
National Institutes of Health
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Link
http://link.springer.com/content/pdf/10.1007/s00280-019-03939-7.pdf
Reference20 articles.
1. Heinrich PC, Castell JV, Andus T (1990) Interleukin-6 and the acute phase response. Biochem J 265(3):621–636
2. Pelliniemi TT, Irjala K, Mattila K, Pulkki K, Rajamaki A, Tienhaara A, Laakso M, Lahtinen R (1995) Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish leukemia group. Blood 85(3):765–771
3. Ljungberg B, Grankvist K, Rasmuson T (1997) Serum interleukin-6 in relation to acute-phase reactants and survival in patients with renal cell carcinoma. Eur J Cancer 33(11):1794–1798
4. Puchalski T, Prabhakar U, Jiao Q, Berns B, Davis HM (2010) Pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma. Clin Cancer Res 16(5):1652–1661. https://doi.org/10.1158/1078-0432.CCR-09-2581
5. Kumari N, Dwarakanath BS, Das A, Bhatt AN (2016) Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol 37(9):11553–11572. https://doi.org/10.1007/s13277-016-5098-7
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Clinical Pharmacology Strategy for Registration in Japan with a Case Example of Posaconazole, a Globally Approved Triazole Antifungal Drug with Broad-spectrum Antifungal Activity;Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics;2024-05-31
2. Therapeutic drug monitoring guidelines in oncology: what do we know and how to move forward? Insights from a systematic review;Therapeutic Advances in Medical Oncology;2024-01
3. The Interaction Between Long Non-Coding RNAs and Cancer-Associated Fibroblasts in Lung Cancer;Frontiers in Cell and Developmental Biology;2022-01-11
4. Interleukin-6 Antagonists: Lessons From Cytokine Release Syndrome to the Therapeutic Application in Severe COVID-19 Infection;Journal of Pharmacy Practice;2021-03-24
5. Modeling and Simulation to Support Phase Ib/IIa Dose Selection for WBP216, A Long Half-Life Fully Human Monoclonal Antibody Against Interleukin-6;Frontiers in Pharmacology;2021-02-18
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3